



1 **LETTER TO THE EDITOR**

2 **Could iodine be effective in the treatment of**  
 3 **human immunodeficiency virus and AIDS-asso-**  
 4 **ciated opportunistic infections?**

5 Retroviruses share similarities in structure, genomic  
 6 organization and replication and are associated with  
 7 immunodeficiencies. AIDS describes the most  
 8 advanced stages of HIV infection and is character-  
 9 ized by a progressive loss of the CD4+ helper subset  
 10 of the T-lymphocytes resulting in immune suppres-  
 11 sion, constitutional diseases and opportunistic  
 12 infections. The feline immunodeficiency retrovirus  
 13 (FIV) has a clinical pathology not unlike that of HIV/  
 14 AIDS, including AIDS-related complexes and chronic  
 15 immunodeficiency.<sup>1–2</sup> In an uncontrolled case study,  
 16 it was found that an adult cat diagnosed with end-  
 17 stage FIV recovered within eight weeks of treatment  
 18 with a daily oral gavage of a commercially available  
 19 iodine solution (tincture of iodine (2.5% w/v), 4 µg  
 20 in 10 ml water, three times daily). Moreover, for at  
 21 least five years there was no further clinical evi-  
 22 dence of disease in this cat. The animal’s recovery  
 23 may have been due to iodine’s broad spectrum  
 24 therapeutic effect on opportunistic infections, or  
 25 possibly because of suppression of viraemia.

26 In HIV and FIV infection, viral load is dependent  
 27 on the stage of infection, however it generally  
 28 predominates in cells of the reticulo-endothelial  
 29 system. Iodine is commonly prepared in two forms:  
 30 conjugated with a cation, which is soluble in aqu-  
 31 eous media, or complexed as two molecules which  
 32 has lipophylic properties. A number of studies have  
 33 demonstrated that iodine, and in particular the  
 34 lipophylic form, possesses potent antiviral and  
 35 microbiocidal properties in vitro.<sup>3–4</sup> The triglycer-  
 36 ide-rich lipoproteins, including chylomicrons and  
 37 very low-density lipoproteins, serve as an energy  
 38 substrate for inflammatory cells. It is our contention  
 39 that the lipophylic form of iodine, when ingested  
 40 orally, may be particularly effective as a microbio-  
 41 cidal/antiviral agent, because it would be incorpo-  
 42


43 rated into chylomicrons, transported via the  
 44 lymphatic system and be delivered to the cells of  
 45 the reticulo-endothelial system.

46 A Folch extraction of the commercial preparation  
 47 of iodine used to treat the cat with FIV was carried  
 48 out in order to explore the relative abundance of the  
 49 lipophylic and hydrophilic form of iodine. The absor-  
 50 bance profiles of the aqueous and solvent phases  
 51 found that the iodine suspension contained both  
 52 forms, with a distribution of approximately one  
 53 third as the more potent antiviral lipophylic moiety.

54 Absorption and distribution of iodine was deter-  
 55 mined by isotopic tracer studies in lymph cannu-  
 56 lated and intact rodents. In cannulated rats, lymph  
 57 delivery of iodine peaked at approximately 2 hour  
 58 following infusion of iodine into the duodenum (see  
 59 [Figure 1](#)) and was complete after 6 hour. Analysis of  
 60 the chylomicron versus non-lipoprotein fraction of  
 61 lymph found that iodine was distributed essentially  
 62 equally ([Figure 1](#)).

63 The pattern of plasma iodine concentration admi-  
 64 nistered to intact animals by oral gavage ([Figure 1](#))  
 65 was consistent with a phase of rapid delivery and  
 66 thereafter at increasing concentration as plasma  
 67 lipoproteins (data not shown). The tissue distribu-  
 68 tion of iodine was determined 4 hour post gavage in  
 69 intact animals. It was found that concentration was  
 70 greatest in the spleen per unit weight of tissue and  
 71 some 1.6-fold greater than in thyroid, liver or mus-  
 72 cle tissue.

73 Inhibiting opportunistic infections or viral load  
 74 may reduce or prevent some of the clinical mani-  
 75 festations associated with retroviral infections.  
 76 Incorporating microbiocidal compounds into trigly-  
 77 ceride-rich lipoproteins may enhance delivery to  
 78 cells harboring bacteria and viruses. The authors’  
 79 pilot studies suggest that using a common prepara-  
 80 tion of iodine, significant quantities of the lipophylic  
 81 form were incorporated into chylomicrons and  
 82 delivered to cells of the reticulo-endothelial sys-  
 83 tem. Based on the relative distribution of iodine



**Figure 1** Approximately 4  $\mu\text{g}$  of radiolabelled iodine suspended in water was given by oral gavage and the concentration in plasma determined. In lymph-cannulated animals, iodine was introduced via a cannula placed directly into the duodenum. Data are expressed as a percentage of the dose given. CM = lymph chylomicron.

found in plasma and lymph (i.e. as a percentage of the dose administered), concentrations known to be effective in vitro could be readily achieved by oral ingestion. These observations are presented in the context of hypothesis generating and have not considered different iodine preparations, species or the dose of iodine administered. Of particular interest would be the putative effects of iodine preparations in modulating viral load which needs to be explored in animal models at different stages of disease.

*Conflict of interest:* No conflict of interest to declare.

## References

1. Olmsted RA, Barnes AK, Yamamoto JK, Hirsch VM, Purcell RH, Johnson PR. *Proc Natl Acad Sci USA* 1989;**86**:2448–52.
2. Hopper CD, Sparkes AH, Gruffydd-Jones TJ, Crispin SM, Muir P, Harbour DA, et al. *Vet Rec* 1989;**125**:341–6.
3. Highsmith F, Xue H, Chen X, Benade L, Owens J, Shanbrom E, et al. *Blood* 1995;**86**:791–6.
4. Kawana R, Kitamura T, Nakagomi O, Matsumoto I, Arita M, Yoshihara N, et al. *Dermatology* 1997;**195**(Suppl 2):29–35.

John C.L. Mamo<sup>\*,a,b</sup>  
Mary Naissides<sup>a,b</sup>

<sup>a</sup>*School of Public Health, Curtin University  
Bentley Campus, Perth, West Australia 6458  
Australia*

<sup>b</sup>*Western Australian Biomedical Research Institute  
Curtin University of Technology, G.P.O. Box U1987  
Perth, Western Australia 6845, Australia*

\*Corresponding author. Tel.: +61 8 266 7232  
fax: +61 8 9266 2958  
E-mail address: j.mamo@curtin.edu.au

Corresponding Editor: Salim Abdool Karim, Durban  
South Africa

6 September 2004

Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

SCIENCE @ DIRECT®